104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
NCT00664573
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
339
Enrollment
INDUSTRY
Sponsor class
Stopped
Analysis of data from 104RA202 failed to meet primary endpoint
Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL:
Baminercept alfa (BG9924)
Sponsor
Biogen